Endologix begins trial geared towards US cuff approval:
This article was originally published in Clinica
Executive Summary
Endologix, of Irvine, California, has started a multicentre, controlled investigational device exemption (IDE) trial intended to support US FDA approval of the large 34mm diameter Powerlink infrarenal cuff in conjunction with the firm's Powerlink product. Powerlink is a bifurcated endoluminal stent graft (ELG) approved by the FDA for the minimally-invasive treatment of abdominal aortic aneurysm (AAA). It is estimated that 35,000 ELG procedures will be performed in the US this year.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.